Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Qingdao NovelBeam Technology Co.,Ltd. (688677.SS)
CNY82.01
-3.49 (-4.08%)
CN SHH Healthcare Medical - Instruments & Supplies
Address
No.100 Keyuanweisi Road 266100
Qingdao, CN
Qingdao, CN
CEO
Yao Zheng
Website
novelbeam.com
IPO
2021-02-26
ISIN CNE100005410
Description
Qingdao NovelBeam Technology Co., Ltd. is a global provider of optical components and advanced solutions for the medical, life science, laser, and micro-display projection industries. Its comprehensive offerings include specialized medical endoscopy devices such as endoscopes, camera couplers, camera lenses, and light source modules. Additionally, the company supplies a range of optical products covering medical optics, industrial and laser applications, and biometric systems. Established in 2003, the firm maintains its headquarters in Qingdao, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY82.01
-3.49 (-4.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.61
Float Shares
118.42M
Free Float %
98.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.35% | +12.98% | +40.89% | +237.43% | +247.96% | +259.08% | +275.35% | +130.87% | +93.46% | +285.91% | +285.91% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
82.01
DCF (Unlevered)
55.09
-32.8%
DCF (Levered)
46.70
-43.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
43.99
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Instruments & Supplies: +7.9%+36.1% ★ Q1'26: +18.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+28.6% ★ Q1'26: +2.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.1% Q1'26: +24.8% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+31.7% ★ Q1'26: +31.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+19.7% ★ Q1'26: +21.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.4% ★ Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.59× ★ Q1'26: 0.45× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
309.67M
est: 309.96M (-0.1%)
|
476.82M
est: 473.69M (+0.7%)
|
470.60M
est: 423.21M (+11.2%)
|
442.83M
est: 439.00M (+0.9%)
|
602.61M
est: 601.00M (+0.3%)
|
725.00M
705.60M – 744.40M
+20.6% YoY
|
884.67M
872.49M – 896.84M
+22.0% YoY
|
1.08B
1.06B – 1.10B
+22.4% YoY
|
| EBITDA |
143.31M
est: 135.53M (+5.7%)
|
219.78M
est: 207.12M (+6.1%)
|
183.54M
est: 175.87M (+4.4%)
|
178.87M
est: 182.43M (-2.0%)
|
217.05M
est: 249.75M (-13.1%)
|
301.28M
293.22M – 309.34M
+20.6% YoY
|
367.63M
362.57M – 372.69M
+22.0% YoY
|
449.92M
441.08M – 458.75M
+22.4% YoY
|
| EBIT |
133.59M
est: 122.37M (+9.2%)
|
205.86M
est: 187.01M (+10.1%)
|
160.71M
est: 158.05M (+1.7%)
|
152.99M
est: 163.95M (-6.7%)
|
191.17M
est: 224.45M (-14.8%)
|
270.76M
263.52M – 278.00M
+20.6% YoY
|
330.39M
325.84M – 334.94M
+22.0% YoY
|
404.34M
396.39M – 412.28M
+22.4% YoY
|
| Net Income |
117.73M
est: 117.39M (+0.3%)
|
182.57M
est: 179.98M (+1.4%)
|
145.71M
est: 126.93M (+14.8%)
|
135.35M
est: 132.28M (+2.3%)
|
170.74M
est: 312.22M (-45.3%)
|
215.50M
213.37M – 230.74M
-31.0% YoY
|
278.46M
269.72M – 287.20M
+29.2% YoY
|
345.99M
337.15M – 354.82M
+24.3% YoY
|
| SGA |
42.63M
est: 17.96M (+137.4%)
|
55.64M
est: 27.45M (+102.7%)
|
69.23M
est: 53.39M (+29.7%)
|
76.31M
est: 55.38M (+37.8%)
|
34.34M
est: 75.82M (-54.7%)
|
91.46M
89.01M – 93.91M
+20.6% YoY
|
111.60M
110.07M – 113.14M
+22.0% YoY
|
136.58M
133.90M – 139.27M
+22.4% YoY
|
| EPS |
1.01
est: 0.97 (+4.0%)
|
1.50
est: 1.49 (+0.7%)
|
1.20
est: 1.04 (+15.2%)
|
1.12
est: 1.11 (+0.9%)
|
1.44
est: 2.62 (-45.0%)
|
1.86
1.79 – 1.94
-28.9% YoY
|
2.34
2.26 – 2.41
+25.4% YoY
|
2.90
2.83 – 2.98
+24.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
222.11M
OE per share TTM
1.87
Owner's Yield
1.21%
Maintenance CapEx ratio
42.57%
Maint CapEx / Avg PPE
82.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 134.1K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 109.6K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 53.8K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
227.3K
Shares Outstanding
119.88M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changming Gu | Deputy GM, Technical Director & Director | — | male |
| Fanghua Wang | Deputy GM, Chief Financial Officer & Board Secretary | — | male |
| Min Ma | Director of Operations Management Center | — | female |
| Mingming Chen | Accounting Supervisor | — | — |
| Rongzhuang Mao | General Manager of OMEK Healthcare | — | male |
| Yao Zheng | GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688677.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
